Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Bommareddy, Praveen K., Rabkin, Samuel D., Kaufman, Howard L.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Author's View
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422399/
https://ncbi.nlm.nih.gov/pubmed/30906668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1571390
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars